I am excited by the launch of EMBO Molecular Medicine, which marks a new era in the activities of the European Molecular Biology Organization (EMBO). The Journal offers a new vehicle for exploration of one of the most promising frontiers in the life sciences. At the same time, for me personally, it also completes a circle with regard to my scientific interests. After training in the 1980s as a medical doctor (with the aim of becoming a hepatologist), I became-at a time when medicine was still more an 'empirical art' than a hard sciencemore and more fascinated by the power of molecular biology. My fascination took me deeply into mechanistic molecular aspects of (post-transcriptional) gene regulation, and considerably further away from medicine than I had anticipated. However, with a growing appreciation of the potential of 'Molecular Medicine', I benefited from astute observations made in 'the clinic' that gave rise to new and important insights into basic mechanisms of gene regulation. b-Thalassaemia and nonsensemediated (mRNA) decay as well as thrombophilia and altered mRNA 3 0 -end processing are personal examples of discoveries that emerged from 'the clinic' rather than from the study of model systems.
» The journal offers a new vehicle for exploration of one of the most promising frontiers in the life sciences.« Conversely, the opportunities of 'bench-to-bedside' research are far better known, and my group actively pursues these in the context of diseases of iron metabolism such as overload and anaemias.
EMBO as a basic life science organization is known for its commitment to excellence, recognition and fostering of scientific talent and last but not the least collegiality. 
